Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for ISTRADEFYLLINE
- Istradefylline Effect Protocol on Parkinson's Disease Tremor
- Adenosine 2A Receptor Antagonism and AIH in ALS
- Istradefylline for Parkinson Disease With Cognitive Impairment
- Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury
- Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
- A Study to Evaluate Abuse Potential of Istradefylline
- Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline
- The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.
- A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
- Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients
- Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
- A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
- 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
- 12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
- A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
- A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
- Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa
- Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome
- A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
- A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa
- A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
- A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
- An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
- An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
- A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
Clinical trials list
click for details